Mer­ck shakes hands with Ac­celeron; Fi­nal­ly, a pill for Covid-19; The past and fu­ture of con­tract re­search; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

You may re­mem­ber from the be­gin­ning of this year that End­points News’ 2021 plan is to go broad­er and deep­er. As part of that ef­fort, we will be launch­ing a new week­ly newslet­ter — End­points Mar­ket­ing Rx — to cov­er all things phar­ma mar­ket­ing. You can sign up the same way some of you signed up for this re­port: by vis­it­ing your read­er pro­file.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.